Drug intelligence / Profile preview

BMN 355

Development stage: Discontinued
Lead developer: BioMarin
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

BMN 355 is a monoclonal antibody developed by BioMarin Pharmaceutical intended to treat long QT syndrome types 2 and 3, a genetic condition that impairs proper electrical function in the heart and can lead to abnormal heart rhythms. The drug was designed as a disease-modifying therapy for this condition, which currently has no approved treatments that modify the disease course. BMN 355 was in preclinical development with plans for global clinical trials initially targeted for around 2025. However, BioMarin discontinued development of BMN 355 in early 2024 as part of a strategic portfolio prioritization, not due to safety concerns but to focus on other pipeline assets[1][2][5][9].

Other names: BMN-355BMN355BMN 355

Beyond the preview

Go deeper on BMN 355.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMN 355.

Explore the full profile